Sutro Biopharma, Inc. (STRO) - Q1 2026 Filing Summary
Business Context and Reporting Period
This summary covers Sutro Biopharma, Inc.'s Form 10-Q for the quarterly period ended March 31, 2026. Sutro is a clinical-stage oncology company developing site-specific antibody-drug conjugates (ADCs) using its proprietary XpressCF and XpressCF+ platforms. The company has no approved commercial products and relies on collaboration revenue and capital markets for funding. As of the filing date, the company is classified as a smaller reporting company and a non-accelerated filer.
Key Financial Metrics
| Metric (in thousands) | Q1 2026 | Q1 2025 |
|---|---|---|
| Revenue | $14,523 | $17,399 |
| Net Loss | $(38,484) | $(75,968) |
| Loss Per Share (Basic & Diluted) | $(2.94) | $(9.08) |
| Cash, Cash Equivalents, and Marketable Securities | $202,558 | $141,428 |
| Accumulated Deficit | $(1,016,439) | $(862,837) |
| Net Cash Used in Operating Activities | $(42,259) | $(67,883) |
| Net Cash Provided by Financing Activities | $103,075 | $66 |
Material Changes vs. Prior Period
- Revenue Decline: Total revenue decreased by 17% ($2.9 million) compared to Q1 2025. This was primarily driven by a $2.4 million decrease in revenue from the Astellas collaboration and a $0.2 million decrease from Vaxcyte.
- Significant Cost Reductions:
- Operating Expenses: Decreased by 49% ($41.7 million) to $44.2 million.
- Restructuring Costs: Dropped significantly from $21.0 million in Q1 2025 to $0.042 million in Q1 2026, as the major restructuring plans (March and September 2025) were substantially completed.
- R&D Expenses: Decreased by 29% ($15.0 million) due to reduced personnel costs and deprioritization of the luvelta program, partially offset by a $7.1 million charge for a negotiated resolution on technology transfer costs.
- G&A Expenses: Decreased by 43% ($5.7 million) due to lower personnel and outside service costs.
- Capital Raise: In February 2026, the company completed an underwritten public offering of 7.9 million shares at $13.98 per share, generating approximately $110.0 million in gross proceeds (net proceeds of ~$103.1 million). This significantly improved liquidity compared to the prior year.
- Stock Split: A 1-for-10 reverse stock split was implemented in December 2025 to regain compliance with Nasdaq listing requirements. All prior period share data has been adjusted retroactively.
Outlook, Management Commentary, and Risks
- Liquidity: Management believes current cash, cash equivalents, and marketable securities ($202.6 million) are sufficient to fund operations for at least the next 12 months. However, the company expects to continue incurring substantial losses and will need additional capital to advance its pipeline.
- Pipeline Progress:
- STRO-004: The lead wholly-owned candidate (Tissue Factor ADC) initiated a Phase 1 trial in November 2025. Dosing for dose level 3 began in February 2026. Preliminary data is expected in mid-2026.
- STRO-006: IND-enabling activities are underway for this Integrinβ6-targeting ADC, with a potential IND submission in 2026.
- STRO-227: A dual-payload ADC targeting PTK7; IND submission is anticipated in late 2026.
- Collaboration Milestones: The company earned a $10.0 million contingent payment from Astellas in Q1 2026 for the initiation of dosing in a Phase 1 clinical trial for the first target program. This payment was recorded as a receivable and recognized as revenue.
- Key Risks:
- Delisting Risk: While the company regained Nasdaq compliance via the reverse stock split, it faces ongoing risk if the stock price falls below $1.00 again.
- Development Risk: Product candidates are in early stages; clinical trials may fail, or regulatory approval may be delayed or denied.
- Manufacturing: The company has exited its internal GMP facility and relies entirely on third-party CDMOs, introducing supply chain risks.
- Deferred Royalty Obligation: A significant non-current liability of $229.1 million exists related to the sale of future Vaxcyte royalties to Blackstone, which incurs substantial non-cash interest expense (~$9.5 million per quarter).
Investor Verification Checklist
- Verify the timing and magnitude of the $10.0 million Astellas milestone payment and its impact on cash flow (received in April 2026 per cash flow notes).
- Confirm the status of the Phase 1 trial for STRO-004 and the timeline for preliminary data release (mid-2026).
- Monitor the company's cash burn rate relative to the $202.6 million liquidity position to assess the runway for future capital raises.
- Review the details of the $7.1 million technology transfer charge included in R&D expenses to understand the nature of the negotiated resolution.
- Track the stock price relative to the $1.00 Nasdaq minimum bid price requirement to assess delisting risk.
- Assess the impact of the $229.1 million deferred royalty obligation on the balance sheet and the associated non-cash interest expense.